Royle, Kara-Louise
92  results:
Search for persons X
?
3

P-206: Antibodies to omicron variants are maintained in new..:

Asher, Samir ; Faustini, Sian ; paterson, Andrea...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S148-S149 , 2022
 
?
9

The Impact of Thalidomide, Zoledronate and High-dose Therap..:

Cairns, David ; Royle, Kara-Louise ; Gregory, Walter...
Clinical Lymphoma Myeloma and Leukemia.  17 (2017)  1 - p. e121-e122 , 2017
 
?
10

Temporary treatment cessation versus continuation of first-..:

Brown, Janet ; Royle, Kara-Louise ; Gregory, Walter...
Brown , J , Royle , K-L , Gregory , W , Ralph , C , Maraveyas , A , Din , O , Eisen , T , Nathan , P , Powles , T , Griffiths , R , Jones , R , Vasudev , N , Wheater , M , Hamid , A , Waddell , T , McMenemin , R , Patel , P , Larkin , J , Faust , G , Martin , A , Swain , J , Bestall , J , McCabe , C , Meads , D , Goh , V , Wah , T M , Brown , J , Hewison , J , Selby , P & Collinson , F 2023 , ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ' , The Lancet Oncology , vol. 24 , no. 3 , pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8.  , 2023
 
?
12

Temporary treatment cessation versus continuation of first-..:

Brown, Janet E ; Royle, Kara-Louise ; Gregory, Walter...
STAR Investigators , Brown , J E , Royle , K-L , Gregory , W , Ralph , C , Maraveyas , A , Din , O , Eisen , T , Nathan , P , Powles , T , Griffiths , R , Jones , R , Vasudev , N , Wheater , M , Hamid , A , Waddell , T , McMenemin , R , Patel , P , Larkin , J , Faust , G , Martin , A , Swain , J , Bestall , J , McCabe , C , Meads , D , Goh , V , Min Wah , T , Brown , J , Hewison , J , Selby , P & Collinson , F 2023 , ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ' , Lancet Oncology , vol. 24 , no. 3 , pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8.  , 2023
 
?
15

Frailty-adjusted therapy in Transplant Non-Eligible patient..:

Coulson, Amy Beth ; Royle, Kara-Louise ; Pawlyn, Charlotte...
http://sro.sussex.ac.uk/id/eprint/106560/1/BMJ%20open%20protocol%20for%20MXIV.pdf.  , 2022
 
1-15